- Home
- SHLS vs OPK Comparison
SHLS vs OPK Comparison
Compare SHLS & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHLS
- OPK
- Stock Information
- Founded
- SHLS 1996
- OPK 2007
- Country
- SHLS United States
- OPK United States
- Employees
- SHLS N/A
- OPK N/A
- Industry
- SHLS Semiconductors
- OPK Biotechnology: Pharmaceutical Preparations
- Sector
- SHLS Technology
- OPK Health Care
- Exchange
- SHLS Nasdaq
- OPK Nasdaq
- Market Cap
- SHLS 978.0M
- OPK 1.1B
- IPO Year
- SHLS 2021
- OPK 1995
- Fundamental
- Price
- SHLS $5.84
- OPK $1.37
- Analyst Decision
- SHLS Buy
- OPK Buy
- Analyst Count
- SHLS 24
- OPK 4
- Target Price
- SHLS $9.44
- OPK $2.75
- AVG Volume (30 Days)
- SHLS 5.8M
- OPK 2.6M
- Earning Date
- SHLS 08-05-2025
- OPK 08-06-2025
- Dividend Yield
- SHLS N/A
- OPK N/A
- EPS Growth
- SHLS N/A
- OPK N/A
- EPS
- SHLS 0.11
- OPK N/A
- Revenue
- SHLS $388,762,000.00
- OPK $689,408,000.00
- Revenue This Year
- SHLS $11.35
- OPK N/A
- Revenue Next Year
- SHLS $11.58
- OPK $6.98
- P/E Ratio
- SHLS $53.69
- OPK N/A
- Revenue Growth
- SHLS N/A
- OPK N/A
- 52 Week Low
- SHLS $2.71
- OPK $1.21
- 52 Week High
- SHLS $7.00
- OPK $2.04
- Technical
- Relative Strength Index (RSI)
- SHLS 56.30
- OPK 51.75
- Support Level
- SHLS $5.51
- OPK $1.34
- Resistance Level
- SHLS $6.16
- OPK $1.45
- Average True Range (ATR)
- SHLS 0.31
- OPK 0.05
- MACD
- SHLS -0.03
- OPK 0.00
- Stochastic Oscillator
- SHLS 56.55
- OPK 38.46
About SHLS Shoals Technologies Group Inc.
Shoals Technologies Group is a provider of electrical balance of system solutions for solar energy projects, primarily in the United States. EBOS encompasses components that are necessary to carry electric current produced by solar panels to an inverter. The products are sold principally to engineering, procurement, and construction firms that build solar energy projects.
About OPK OPKO Health Inc.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.